Justice Dept. Reclassifies Medical Marijuana, Boosts Psychedelic Research

0:00On April 25, the Justice Department just dropped a bombshell on federal drug policy, reclassifying state licensed medical marijuana from schedule. One to schedule three under the Control Substances Act. This follows President Trump's December Executive Order, signed off by Acting Attorney General Todd Blanche on Thursday. Meanwhile, their fast-tracking psychedelic reviews like Silas Ivan and Ibo Gain for treating mental health issues. They also kicked off an expedited hearing starting June 29 to tackle broader cannabis changes, picking up speed after the process stalled. Before, this marks some of the biggest shifts in decades especially from a Republican admin once dead said against loosening drug laws. For the cannabis world, it's a game-changer right away. State operators can now deduct normal business expenses dodging that old IRS code 280E. Researchers give fewer roadblocks too. But the industry is divided with folks holding recreational licenses still stuck in limbo

1:02until that hearing wraps. On the psychedelics front, Trump's April 18 order pushed the FDA to prioritize breakthrough therapies handing out commissioners national. Priority vouchers to speed things up, first time for any psychedelic. That led to vouchers for Silas Ivan on treatment-resistant depression and meth alone for PTSD, plus clearing an early trial for Norobo Gain on alcohol, use disorder. They even pledged at least $50 million through ARPA-H for state research. These moves ease past to potential treatments without flipping federal legalization switches. All psychedelics and recreational weed stay schedule one. For now. But the momentum's building fast toward real relief. From across the country, powered by AI, this is US News Today.